Diet Modifies Pioglitazone’s Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression

Figure 1

Effects of Pio on WT and PPARγ KO mice. (a) Weight (indexed to initial weight), (b) lean mass (g), (c) fat mass (g), (d) fat mass (expressed as fraction of total mass), (e) serum insulin (mIU/mL, nonfasting a.m.), (f) blood glucose (mg/dL, nonfasting a.m.), (g) serum free fatty acids (FFA) (mM, nonfasting a.m.), and (h) liver triglycerides (mg/g liver) in wildtype (WT) and liver-specific PPARγ knockout (KO) mice given a control or high-fat diet (HFD) unsupplemented or supplemented with Pioglitazone (Pio). vs. corresponding control diet-treated group; vs. corresponding Pio-treated group; vs. all other WT groups; vs. corresponding HFD-treated group; vs. corresponding WT group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)